The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Novartis Pharmaceuticals Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
- 2025 (10)
- 2024 (20)
- 2023 (44)
- 2022 (38)
- 2021 (36)
- 2020 (58)
- 2019 (31)
- 2018 (47)
- 2017 (11)
- 2016 (44)
- 2015 (37)
- 2014 (10)
- 2013 (12)
- 2012 (6)
- 2011 (6)
- 2010 (28)
- 2009 (4)
- 2008 (15)
- 2007 (1)
- 2006 (4)
- 2005 (11)
- 2004 (4)
- 2003 (5)
- 2002 (7)
- 2001 (5)
- 2000 (8)
- 1999 (2)
- 1998 (2)
- 1997 (4)
- 1996 (4)
- 1995 (4)
- 1993 (10)
- 1992 (3)
- 1991 (16)
Sponsor content
547 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TAFINLAR dabrafenib (as mesilate)10 mg dispersible tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MEKINIST trametinib (as dimethyl sulfoxide) 0.05 mg/mL powder for oral solution bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 40 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SCEMBLIX asciminib (as hydrochloride) 20 mg film-coated tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for MAYZENT siponimod 1 mg film coated tablet blister pack.
-
Prescription medicine registrationActive ingredients: dabrafenib mesilate.
-
Prescription medicine registrationActive ingredients: trametinib dimethyl sulfoxide.
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd
-
Cancellation by sponsorRequested by Novartis Pharmaceuticals Australia Pty Ltd